BECN1 and gastric cancer: In patients with hepatocellular carcinoma and gastric cancers, reduced Beclin-1 expression is associated with a poor prognosis [40,41], while high expression is associated with favourable prognosis for salivary carcinoma and lymphoma patients [42,43].